- Trials with a EudraCT protocol (10,137)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
10,137 result(s) found for: Standard Treatment.
Displaying page 47 of 507.
| EudraCT Number: 2021-003327-15 | Sponsor Protocol Number: TIDAM | Start Date*: 2022-02-21 |
| Sponsor Name:Erasmus MC | ||
| Full Title: An open-label, 8-week, proof of concept trial on thymosin-α1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18). | ||
| Medical condition: Primary immunodeficiency | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003258-25 | Sponsor Protocol Number: X16120 | Start Date*: 2019-07-04 | |||||||||||
| Sponsor Name:Odense University Hospital | |||||||||||||
| Full Title: Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial | |||||||||||||
| Medical condition: multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004489-16 | Sponsor Protocol Number: V3_KET_NEG_SYMPT_SCZ | Start Date*: 2021-11-03 |
| Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie | ||
| Full Title: Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study. | ||
| Medical condition: Negative and depressive symptoms of schizophrenia according to DSM-5 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002491-39 | Sponsor Protocol Number: SGNTUC-028 | Start Date*: 2022-02-11 | |||||||||||||||||||||
| Sponsor Name:Seagen Inc. | |||||||||||||||||||||||
| Full Title: A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) | |||||||||||||||||||||||
| Medical condition: Unresectable locally-advanced or metastatic HER2+ breast cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-001040-35 | Sponsor Protocol Number: D3250C00045 | Start Date*: 2017-08-21 | ||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||
| Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled ... | ||||||||||||||||||
| Medical condition: severe uncontrolled asthma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) GB (Completed) FR (Completed) BE (Completed) SE (Completed) NL (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2004-001999-40 | Sponsor Protocol Number: EGF30001 | Start Date*: 2004-11-25 |
| Sponsor Name:GlaxoSmithKline R&D Ltd | ||
| Full Title: A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breas... | ||
| Medical condition: Advanced or metastatic breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005113-73 | Sponsor Protocol Number: 20150114 | Start Date*: 2016-07-01 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation | ||
| Medical condition: Type 2 diabetes with albuminuria | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004011-30 | Sponsor Protocol Number: 987654321 | Start Date*: 2005-12-02 |
| Sponsor Name:Gwent Healthcare NHS Trust | ||
| Full Title: A prospective open study evaluating the use of botulinum toxin in patients with overactive bladder as an alternative to other conservative treatments. | ||
| Medical condition: Overactive bladder syndrome is characterized by a combination of urinary frequency, urgency and urge incontinence. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-018034-11 | Sponsor Protocol Number: 2010vanco.psc | Start Date*: 2013-04-29 |
| Sponsor Name:Karolinska Institutet | ||
| Full Title: Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis | ||
| Medical condition: Primary Sclerosing Cholangitis (PSC) is a progressive disease of the biliary system which might lead to increased risk of cholangiocancer. PSC constitutes a common indication for adult liver transp... | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-019945-24 | Sponsor Protocol Number: BEB-10 | Start Date*: 2010-09-24 |
| Sponsor Name:Birken GmbH | ||
| Full Title: Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epitheliali... | ||
| Medical condition: This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelializati... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003023-22 | Sponsor Protocol Number: 2014-26 | Start Date*: Information not available in EudraCT |
| Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
| Full Title: Open trial with randomized withdrawal of treatment, to evaluate the efficacy of azithromycin in the treatment of bronchiectasis excluding cystic fibrosis in children (AZI-STOP study) | ||
| Medical condition: bronchiectasis excluding cystic fibrosis in children | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020681-16 | Sponsor Protocol Number: LO-10-01 | Start Date*: 2010-10-12 | |||||||||||
| Sponsor Name:Lunamed Operations AG | |||||||||||||
| Full Title: A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIE... | |||||||||||||
| Medical condition: Patients suffering from prostate carcinoma with progression under first line hormonal treatment. Patients entering the study should have a life expectancy prognosis of at least 6 months. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-000716-21 | Sponsor Protocol Number: AP301-III-001 | Start Date*: 2013-06-11 |
| Sponsor Name:Apeptico Forschung und Entwicklung GmbH | ||
| Full Title: Pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in mechanically ventilated patients after primary lung transplantation | ||
| Medical condition: Primary Graft Dysfunction (PGD) after lung transplantation | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-001049-15 | Sponsor Protocol Number: HD-TREX | Start Date*: 2018-08-24 | |||||||||||
| Sponsor Name:ANOVA (Andrologi, Sexualmedicin, Transmedicin) Karolinska Universitetssjukhuset och Umeå Universitet | |||||||||||||
| Full Title: Pharmacological treatment of hypersexual disorder; an open pilot study to evaluate the feasibility and effectiveness of treatment with Naltrexone | |||||||||||||
| Medical condition: Hypersexual disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-004444-30 | Sponsor Protocol Number: Disc_allo_MSV | Start Date*: 2013-04-23 |
| Sponsor Name:Citospin | ||
| Full Title: Treatment of degenerative disc disease with allogenic mesenchymal cells—MSV-- | ||
| Medical condition: Treatment of degenerative disc disease | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004975-22 | Sponsor Protocol Number: ORN-2014-16 | Start Date*: 2015-09-03 |
| Sponsor Name:Oral and Maxillofacial Surgery Department of Vall d'Hebron Hospital | ||
| Full Title: Advances in the management of mandibular osteoradionecrosis: Pentoxyfilline and Tocopherol as medical treatment. | ||
| Medical condition: Assess whether there is a clinically significant reduction in intraoral bone exposure (measured in mm) in the experimental group after the start of treatment with pentoxifylline and tocopherol (PEN... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-002159-89 | Sponsor Protocol Number: NLD-PEG-14-10784 | Start Date*: 2015-11-05 |
| Sponsor Name:Biogen MA | ||
| Full Title: Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a | ||
| Medical condition: Erythema at injection site after Plegridy injection for the treatment of Multiple Sclerose. | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-003567-20 | Sponsor Protocol Number: A101A | Start Date*: 2017-04-21 |
| Sponsor Name:Dept of Infectious Diseases, Aarhus University Hospital | ||
| Full Title: A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI... | ||
| Medical condition: Latent tuberculosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-002947-41 | Sponsor Protocol Number: N19PCA | Start Date*: 2019-11-20 |
| Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek | ||
| Full Title: Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO). | ||
| Medical condition: Angiosarcoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-004604-20 | Sponsor Protocol Number: AGO/2018/007 | Start Date*: 2019-12-03 |
| Sponsor Name:Ghent University Hospital | ||
| Full Title: Myo-inositol versus clomiphene citrate as first line treatment for ovulation induction in PCOS | ||
| Medical condition: Polycystic ovary syndrome (PCOS) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.